Impact of SARS-CoV-2 infection on liver disease

dc.contributor.authorSalgüero Fernández, Sergio
dc.contributor.authorGabriel Medina, Pablo
dc.contributor.authorAlmería Lafuente, Alejandro
dc.contributor.authorBallesteros Vizoso, María Antonieta
dc.contributor.authorZamora Trillo, Angielys
dc.contributor.authorCasals Mercadal, Gregori
dc.contributor.authorSolé Enrech, Gemma
dc.contributor.authorLalana Garcés, Marta
dc.contributor.authorGuerra Ruiz, Armando R.
dc.contributor.authorOrtiz Pastor, Oihana
dc.contributor.authorMorales Ruiz, Manuel
dc.date.accessioned2024-03-27T13:31:01Z
dc.date.available2024-03-27T13:31:01Z
dc.date.issued2023-07-11
dc.date.updated2023-07-11T07:54:18Z
dc.description.abstractIntroduction: Abnormal liver biochemistry is not a rare finding in the context of SARS-CoV-2 infection, regardless of patients having pre-existing chronic disease or not Content: This review examines the current body of knowledge on the relationship between COVID-19 and liver injury, which is frequently found in this setting Summary: Although the pathogenesis of liver injury is not fully understood, it has been suggested to be the result of a combination of multiple factors. These include direct injury caused by the virus, immune system hyperactivation, ischemic and drug-induced injury. The prognostic valor of these alterations is also the subject of intense research. Due to their potential impact, these alterations require proper management and treatment, especially in patients with chronic liver disease or liver transplant recipients. Outlook: Some aspects associated with liver injury during COVID-19, especially in severe presentations, are not well understood. Studies assessing the clinical impact of COVID-19 on the healthy or diseased liver may help adjust treatment and immunization guidelines to the profile of the patient. © 2022 Sergio Salgüero Fernández et al., published by De Gruyter, Berlin/Boston.
dc.format.extent8 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idimarina9330064
dc.identifier.issn2628-491X
dc.identifier.pmid37361869
dc.identifier.urihttps://hdl.handle.net/2445/209294
dc.language.isoeng
dc.publisherWalter De Gruyter Gmbh
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1515/almed-2022-0037
dc.relation.ispartofAdvances In Laboratory Medicine, 2022, vol. 3, num. 2, p. 126-133
dc.relation.urihttps://doi.org/10.1515/almed-2022-0037
dc.rightscc by (c) Salgüero Fernández, Sergio et al, 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
dc.subject.classificationMalalties del fetge
dc.subject.classificationSARS-CoV-2
dc.subject.otherLiver diseases
dc.titleImpact of SARS-CoV-2 infection on liver disease
dc.typeinfo:eu-repo/semantics/other
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
Impact of SARS-CoV-2 infection on liver disease_AdvLabMed.pdf
Mida:
876.9 KB
Format:
Adobe Portable Document Format